A Safety and Immunogenicity Phase 1 Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31) Administered at 0 and 2 Months.

Trial Profile

A Safety and Immunogenicity Phase 1 Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31) Administered at 0 and 2 Months.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2013

At a glance

  • Drugs H1IC; Tuberculosis vaccine
  • Indications Tuberculosis
  • Focus Adverse reactions
  • Sponsors Statens Serum Institut
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top